Fracture and Bone Mineral Density Response by Baseline Risk in Patients Treated With Abaloparatide Followed by Alendronate: Results From the Phase 3 ACTIVExtend Trial

In the randomized, placebo‐controlled, double‐blind phase 3 ACTIVE study (NCT01343004), 18 months of abaloparatide 80 μg daily (subcutaneous injection) in postmenopausal women at risk of osteoporotic fracture significantly reduced the risk of vertebral, nonvertebral, clinical, and major osteoporotic...

Descripción completa

Detalles Bibliográficos
Autores principales: Leder, Benjamin Z, Zapalowski, Carol, Hu, Ming‐Yi, Hattersley, Gary, Lane, Nancy E, Singer, Andrea J, Dore, Robin K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916366/
https://www.ncbi.nlm.nih.gov/pubmed/31411768
http://dx.doi.org/10.1002/jbmr.3848

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916366/
https://www.ncbi.nlm.nih.gov/pubmed/31411768
http://dx.doi.org/10.1002/jbmr.3848

Ejemplares similares